文献速递银屑病与炎症性皮肤病

Tapinarof 1%乳膏每日一次治疗斑块状银屑病的患者报告结局:PSOARING 3试验

Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial.
PubMed 文献 · J Am Acad Dermatol · 2023-05-10

PSOARING 3是一项开放标签扩展研究,纳入完成两项12周III期试验的轻至重度斑块状银屑病成人患者,评估tapinarof 1%乳膏每日一次长期治疗的健康相关生活质量和患者满意度。结果显示DLQI评分改善并维持,第40周时68.0%患者DLQI为0或1,多数患者对疗效、应用便利性和化妆品优雅性表示满意。

要点

  • 第40周时68.0%患者DLQI为0或1,表明银屑病对健康相关生活质量无影响。
  • 62.9%-85.8%患者对tapinarof的信心和疗效满意度表示强烈同意或同意。
  • 79.9%-96.3%患者对应用便利性和化妆品优雅性表示满意。

核心结论

  • 持续和持久的健康相关生活质量改善、高患者满意度和对tapinarof 1%乳膏的积极认知得到证实。

研究设计与样本

  • 开放标签扩展研究,纳入完成两项12周III期试验的轻至重度斑块状银屑病成人患者,基于医生全球评估进入40周开放标签tapinarof治疗,随访4周。
  • 共有763例(91.6%)合格患者入组,78.5%完成患者满意度问卷。

主要发现

  • DLQI评分改善并维持。
  • 第40周时68.0%患者DLQI为0或1,表明银屑病对健康相关生活质量无影响。
  • 大多数患者对所有患者满意度问卷问题表示强烈同意或同意:对tapinarof的信心和疗效满意度为62.9%-85.8%,应用便利性和化妆品优雅性为79.9%-96.3%,对tapinarof与既往银屑病治疗的偏好为55.3%-81.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 开放标签。
  • 无对照。
  • 可能不能推广至所有类型的银屑病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tapinarof cream 1% once daily demonstrated significant efficacy versus vehicle and was well tolerated in two 12-week, phase 3 pivotal trials in adults with mild-to-severe plaque psoriasis. OBJECTIVE: To assess long-term, health-related quality of life and patient satisfaction with tapinarof. METHODS: Patients completing the 12-week trials were eligible for 40 weeks of open-label tapinarof based on Physician Global Assessment score in PSOARING 3, with a 4-week follow-up. Dermatology Life Quality Index was assessed at every visit; Patient Satisfaction Questionnaire responses were assessed at week 40 or early termination. RESULTS: Seven hundred sixty-three (91.6%) eligible patients enrolled; 78.5% completed the Patient Satisfaction Questionnaire. DLQI scores improved and were maintained. By week 40, 68.0% of patients had a DLQI of 0 or 1, indicating no impact of psoriasis on health-related quality of life. Most patients strongly agreed or agreed with all Patient Satisfaction Questionnaire questions assessing confidence in tapinarof and satisfaction with efficacy (62.9%-85.8%), application ease and cosmetic elegance (79.9%-96.3%), and preference for tapinarof versus prior psoriasis therapies (55.3%-81.7%). LIMITATIONS: Open-label; no control; may not be generalizable to all forms of psoriasis. CONCLUSIONS: Continued and durable improvements in health-related quality of life, high rates of patient satisfaction, and positive perceptions of tapinarof cream were demonstrated.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Bagel J, Gold LS, Del Rosso J, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial. J Am Acad Dermatol. 2023. PMID: 37172733. doi:10.1016/j.jaad.2023.04.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。